Almost Half Of Patients With Newly Diagnosed BRCA-Mutated Advanced Ovarian Cancer May Be Progression-Free After Receiving Two Years Of Maintenance Olaparib

Healio (10/7, Demko) reports researchers found after five years of follow-up, “almost half of patients with newly diagnosed BRCA-mutated advanced ovarian cancer were progression-free after receiving 2 years of maintenance olaparib.” The findings were presented at the ESMO Virtual Congress 2020